Company Overview
Quince Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the acquisition, development, and commercialization of therapeutics designed for patients suffering from debilitating and rare diseases. The company functions within the broader healthcare sector, specifically targeting the biotechnology industry where innovation focuses on addressing unmet medical needs through specialized drug candidates. Its current operational scale is defined by a market capitalization of $4.88M and an employee count of 36 individuals supporting its research and development efforts. The revenue figure for the trailing twelve months is N/A, which, combined with the small market cap, indicates that the company is in a pre-revenue or early-stage development phase typical of firms focusing on rare disease indications like EryDex.
Financial Health
The financial statements for the trailing twelve months reveal a revenue of N/A and a net income of $-56,979,000, while the EBITDA stands at $-41,683,000. The gap between the zero revenue and the substantial net loss highlights a cost structure dominated by research, development, and operational expenses rather than commercial sales. Free cash flow for the period is $-17,977,500, indicating that the company is burning cash to fund its pipeline and has limited financial flexibility to cover ongoing operational costs without external financing. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting that the company has not yet generated positive cash flow from sales to cover its direct costs or overhead expenses. On the balance sheet, the company holds $26.29M in cash against $17.99M in debt, supported by a debt-to-equity ratio of 1699.06 which suggests a highly leveraged position relative to its equity base. Despite the high leverage, the current ratio of 1.12 indicates that the company maintains adequate short-term liquidity to meet its obligations due to its significant cash reserves. Return on Equity is -247.8% and Return on Assets is -22.1%, metrics that reveal the current inability of management to generate positive returns on capital employed due to the net loss position.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A because the company reports a net loss, while the forward P/E is listed as -0.07, implying that the market prices the stock based on future earnings expectations that have not yet been realized. The price-to-book ratio is 4.61, suggesting that the market values the company's equity at a significant premium relative to its book value, likely due to the potential value of its intellectual property and pipeline assets. Price-to-sales ratio is N/A and the EV/EBITDA is 0.08; these alternative metrics indicate that traditional valuation multiples are not applicable given the lack of revenue and negative earnings, requiring reliance on asset-based or pipeline-driven valuations. The stock has experienced extreme volatility, trading between a 52-week low of $0.08 and a 52-week high of $4.55. If the current price is assumed to be near the recent high, it sits at approximately 0% below the 52-week high of $4.55, whereas a price near the low would place it at 98% below the high, illustrating the wide trading range. The beta value of 1.27 signifies that the stock price is 27% more volatile than the broader market, exposing investors to higher risk fluctuations in price compared to a standard market index.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is also N/A, meaning there are no historical data points to determine if earnings are growing faster or slower than revenue in a traditional sense. As the company does not currently pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which implies that the company reinvests all available resources, including its cash reserves, directly into research and development rather than distributing income to shareholders. This non-dividend status is consistent with the operational profile of a biotechnology firm in the early stages of asset development where capital preservation is prioritized over income distribution. The overall growth and income profile for Quince Therapeutics, Inc. is characterized by an absence of current revenue generation and income distribution, focusing entirely on the long-term potential of its therapeutic candidates for rare pediatric neurodegenerative diseases.